FibroGen, Inc. FGEN
Set alert
9.07 USD 0.00 0.00%
As of Jan 12, 9:30 AM ET
9.02 Day range 9.21
0.18 52-week range 2.93
- YTD
- +3.30%
- 1 year
- -41.90%
- Open
- 9.10
- Prev close
- 9.07
- Mkt cap
- 48.37M
- Vol
- 29.25K
- Avg vol
- 1.21M
- EPS
- -1.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.02
- High
- 9.21
- Forward P/E
- -0.70
- Beta
- 0.73
- Short ratio
- 3.27
- Inst. own
- 55.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.35386
- 200-d avg
- 0.852785
- 1y target
- 10.00
2Y chart
Events in this range
- Feb 26, 2024Earnings: -0.57; estimate -0.42; surprise -35.71%
- May 6, 2024Earnings: -0.33; estimate -0.31; surprise -6.45%
- Aug 6, 2024Earnings: -0.16; estimate -0.26; surprise 38.46%
- Nov 12, 2024Earnings: -0.17; estimate -0.38; surprise 55.26%
- Jun 17, 2025Split: 1 for 25
Signals (94)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 26, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| RSI: Oversold | Dec 2, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| RSI: Oversold | Nov 12, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Aug 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| RSI: Overbought | Aug 12, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 8, 2025 | 1 year ago |
| RSI: Oversold | Jun 17, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| SMA: Bearish | May 30, 2025 | 1 year ago |
| MACD: Sell Signal | May 30, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 26, 2025 | 1 year ago |
| SMA: Bearish | Feb 25, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 20, 2025 | 1 year ago |
| RSI: Overbought | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 11, 2025 | 1 year ago |
| SMA: Bullish | Feb 5, 2025 | 1 year ago |
| SMA: Bearish | Feb 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| RSI: Overbought | Jan 6, 2025 | 1 year ago |
| RSI: Overbought | Dec 24, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
| SMA: Bullish | Dec 19, 2024 | 1 year ago |
| SMA: Bearish | Dec 11, 2024 | 1 year ago |
| SMA: Bullish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 6, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 6, 2024 | 1 year ago |
| SMA: Bullish | Nov 21, 2024 | 1 year ago |
| SMA: Bearish | Nov 15, 2024 | 1 year ago |
| SMA: Bullish | Nov 14, 2024 | 1 year ago |
| SMA: Bearish | Nov 13, 2024 | 1 year ago |
| SMA: Bullish | Nov 12, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 25, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 17, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 8, 2024 | 2 years ago |
| RSI: Oversold | Sep 3, 2024 | 2 years ago |
| RSI: Oversold | Aug 28, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 21, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 31, 2024 | 2 years ago |
| RSI: Oversold | Jul 31, 2024 | 2 years ago |
| SMA: Bearish | Jul 30, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jul 17, 2024 | 2 years ago |
| SMA: Bullish | Jul 16, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| RSI: Oversold | Jul 1, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 27, 2024 | 2 years ago |
| SMA: Bearish | Jun 26, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 24, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 17, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 12, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 11, 2024 | 2 years ago |
| MACD: Buy Signal | May 1, 2024 | 2 years ago |
| RSI: Oversold | Apr 19, 2024 | 2 years ago |
| SMA: Bearish | Apr 3, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 2, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 19, 2024 | 2 years ago |
| RSI: Overbought | Feb 8, 2024 | 2 years ago |
Key statistics
- Market cap
- 48.37M
- Enterprise value
- 103.85M
- Trailing P/E
- 0.00
- Forward P/E
- -0.70
- PEG ratio
- 0.00
- Price / sales
- 0.28
- Price / book
- 0.00
- EPS (TTM)
- -1.23
- Beta
- 0.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -96.84%
- Revenue (TTM)
- 173.82M
- Revenue growth
- 14.30%
- Free cash flow
- -121.83M
- Total cash
- 140.71M
- Total debt
- 163.78M
- Return on equity
- 0.00%
- Shares outstanding
- 100.77M
- Short % of float
- 5.07%
- 50-day average
- 0.35386
- 200-day average
- 0.852785
Analyst view
Consensus: hold
Hold
Price target (mean) 10.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.20.
Financials — quick view
FGEN Revenue — quarterly 1.08M
FGEN Net income — quarterly 200.64M
FGEN EPS — quarterly 49.61
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.38 | -0.17 | +0.21 | +55.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.26 | -0.16 | +0.10 | +38.46% |
| May 6, 2024 | Mar 1, 2024 | -0.31 | -0.33 | -0.02 | -6.45% |
| Feb 26, 2024 | Dec 1, 2023 | -0.42 | -0.57 | -0.15 | -35.71% |
| Nov 6, 2023 | Sep 1, 2023 | -0.68 | -0.52 | +0.16 | +23.53% |
| Aug 7, 2023 | Jun 1, 2023 | -0.72 | -0.65 | +0.07 | +9.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2023 | B of A Securities | down | Neutral | Underperform |
| Jun 27, 2023 | Goldman Sachs | main | Sell | Sell |
| Jun 27, 2023 | Raymond James | down | Outperform | Market Perform |
| Jun 26, 2023 | B of A Securities | down | Buy | Neutral |
| Jun 26, 2023 | Stifel | down | Buy | Hold |
| Jun 26, 2023 | Raymond James | down | Outperform | Market Perform |
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fibrogen.com
News
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
- FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- 12 Health Care Stocks Moving In Monday's After-Market Session
- FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript
- FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
- FibroGen to Report Third Quarter 2025 Financial Results
- FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
- FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Your note
Sign in to keep a note on FGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADIB DEYAA | Officer | Purchase | Jun 11, 2024 | 82,123 |
| BLAUG SUZANNE | Director | Sale | Jun 8, 2023 | 29,594 |
| BRENNAN AOIFE M | Director | Sale | Jun 8, 2023 | 27,947 |
| CHUNG CHRISTINE | Officer | Stock Award(Grant) | Mar 5, 2024 | 341,028 |
| CONTERNO ENRIQUE A | Chief Executive Officer | Sale | Jul 6, 2023 | 402,522 |
| CRAVATT BENJAMIN PH.D. | Director | Sale | Jun 8, 2023 | 28,736 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Management Company | 9.84% | 9,911,231 | 4.76M | Sep 29, 2024 |
| Armistice Capital, LLC | 6.75% | 6,800,000 | 3.26M | Sep 29, 2024 |
| Vanguard Group Inc | 5.84% | 5,882,361 | 2.82M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.88% | 3,905,350 | 1.87M | Sep 29, 2024 |
| Blackrock Inc. | 2.37% | 2,391,439 | 1.15M | Sep 29, 2024 |
| 683 Capital Management LLC | 2.12% | 2,138,402 | 1.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Horizon Fund-Capital Opportunity Fund | 3.95% | 3,980,425 | 1.91M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.89% | 2,916,871 | 1.40M | Sep 29, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 2.62% | 2,635,691 | 1.27M | Sep 29, 2024 |
| Primecap Odyssey Growth Fund | 1.56% | 1,567,085 | 752.20K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 1,380,877 | 662.82K | Sep 29, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.89% | 898,604 | 431.33K | Sep 29, 2024 |